Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation
Abstract ERBB2 mutations are found in about 2% of patients with non‐small cell lung cancer (NSCLC). A recent study reported that pyrotinib (an irreversible pan ErbB inhibitor) had superior antitumor effect compared to other tyrosine kinase inhibitor therapies in patients with ERBB2 mutations. Bone m...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-07-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13480 |
| _version_ | 1831571569970774016 |
|---|---|
| author | Yanyan Wu Jun Ni Xiaoyan Chang Xiaotong Zhang Li Zhang |
| author_facet | Yanyan Wu Jun Ni Xiaoyan Chang Xiaotong Zhang Li Zhang |
| author_sort | Yanyan Wu |
| collection | DOAJ |
| description | Abstract ERBB2 mutations are found in about 2% of patients with non‐small cell lung cancer (NSCLC). A recent study reported that pyrotinib (an irreversible pan ErbB inhibitor) had superior antitumor effect compared to other tyrosine kinase inhibitor therapies in patients with ERBB2 mutations. Bone marrow metastasis is rare in lung adenocarcinoma, and has been reported to be associated with poor prognosis. Here, we report the case of a 62‐year‐old female diagnosed with lung adenocarcinoma and bone marrow metastasis. ERBB2 exon 20 insertion mutation was confirmed by next‐generation sequencing (NGS) of lung tissue as well as bone marrow. The patient achieved stable disease and recovery of pancytopenia after two months of pyrotinib therapy. This is the first report of homogenous mutations of ERBB2 detected in bone marrow, as well as a good response of bone marrow to pyrotinib therapy. Key points This is the first report of a homogenous mutation of ERBB2 detected in the bone marrow of an NSCLC patient with bone marrow metastasis. Our patient with NSCLC ERBB2 mutation and bone marrow metastasis responded well to pyrotinib therapy. |
| first_indexed | 2024-12-17T13:11:14Z |
| format | Article |
| id | doaj.art-32b10ca683664d5b86e587360b5d4a40 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-17T13:11:14Z |
| publishDate | 2020-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-32b10ca683664d5b86e587360b5d4a402022-12-21T21:47:06ZengWileyThoracic Cancer1759-77061759-77142020-07-011172051205510.1111/1759-7714.13480Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutationYanyan Wu0Jun Ni1Xiaoyan Chang2Xiaotong Zhang3Li Zhang4Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaDepartment of Pathology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaAbstract ERBB2 mutations are found in about 2% of patients with non‐small cell lung cancer (NSCLC). A recent study reported that pyrotinib (an irreversible pan ErbB inhibitor) had superior antitumor effect compared to other tyrosine kinase inhibitor therapies in patients with ERBB2 mutations. Bone marrow metastasis is rare in lung adenocarcinoma, and has been reported to be associated with poor prognosis. Here, we report the case of a 62‐year‐old female diagnosed with lung adenocarcinoma and bone marrow metastasis. ERBB2 exon 20 insertion mutation was confirmed by next‐generation sequencing (NGS) of lung tissue as well as bone marrow. The patient achieved stable disease and recovery of pancytopenia after two months of pyrotinib therapy. This is the first report of homogenous mutations of ERBB2 detected in bone marrow, as well as a good response of bone marrow to pyrotinib therapy. Key points This is the first report of a homogenous mutation of ERBB2 detected in the bone marrow of an NSCLC patient with bone marrow metastasis. Our patient with NSCLC ERBB2 mutation and bone marrow metastasis responded well to pyrotinib therapy.https://doi.org/10.1111/1759-7714.13480Bone marrow metastasisERBB2 mutationNSCLCpyrotinib |
| spellingShingle | Yanyan Wu Jun Ni Xiaoyan Chang Xiaotong Zhang Li Zhang Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation Thoracic Cancer Bone marrow metastasis ERBB2 mutation NSCLC pyrotinib |
| title | Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation |
| title_full | Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation |
| title_fullStr | Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation |
| title_full_unstemmed | Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation |
| title_short | Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation |
| title_sort | successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non small cell lung cancer and erbb2 mutation |
| topic | Bone marrow metastasis ERBB2 mutation NSCLC pyrotinib |
| url | https://doi.org/10.1111/1759-7714.13480 |
| work_keys_str_mv | AT yanyanwu successfultreatmentofpyrotinibforbonemarrowmetastasisinducedpancytopeniainapatientwithnonsmallcelllungcanceranderbb2mutation AT junni successfultreatmentofpyrotinibforbonemarrowmetastasisinducedpancytopeniainapatientwithnonsmallcelllungcanceranderbb2mutation AT xiaoyanchang successfultreatmentofpyrotinibforbonemarrowmetastasisinducedpancytopeniainapatientwithnonsmallcelllungcanceranderbb2mutation AT xiaotongzhang successfultreatmentofpyrotinibforbonemarrowmetastasisinducedpancytopeniainapatientwithnonsmallcelllungcanceranderbb2mutation AT lizhang successfultreatmentofpyrotinibforbonemarrowmetastasisinducedpancytopeniainapatientwithnonsmallcelllungcanceranderbb2mutation |